Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

In the late 1960s Miles Vaughan Williams, a member of the staff in the Oxford Department of Pharmacology and Fellow of Hertford College (1955-85), introduced a novel classification of drugs used to treat cardiac arrhythmias. This scheme has been very widely used around the world and has led to the development of new drugs that have saved countless lives. Our understanding of the control of cardiac rhythm has developed in that time and a group of cardiovascular scientists from Oxford, Cambridge and Beijing led by Associate Professor Ming Lei decided that the time was ripe to modernise the classification and to celebrate the centenary of the birth of Vaughan Williams.

Together they have now published a comprehensive modern classification, based upon the original version, in the leading journal ‘Circulation’.

Findings over the past 5 decades from studies of different molecular drug targets, their mechanisms of action, and consequent clinical effects have led to the need to revise the classification. The modernised Oxford classification augments Vaughan Williams’s original framework covering the actions of sodium, potassium and calcium ions and the effects on these of the nervous system (Class I-IV). Novel categories now relate to altered heart rates (Class 0), mechanical stretch (Class V); intercellular electrical communication (Class IV) and longer term structural change (Class VII). The scheme then draws attention to multiple drug targets and actions and possible adverse, even pro-arrhythmic, effects.

This clarified classification of both the actions and therapeutic applications of both established drugs and novel drugs under investigation will improve current and future treatment of cardiac arrhythmias. It will encourage a rational clinical use of existing available anti-arrhythmic drugs in relationship to their particular mechanisms of action. It will aid identification and development of novel drugs relating their future clinical applications to their molecular mechanisms of action.  

The classification commemorates and advances the landmark contributions of Miles Vaughan Williams (https://en.wikipedia.org/wiki/Miles_Vaughan_Williams) to the physiology of the heart that began this quest nearly half a century ago on this centenary of his birth. It is likely that the new classification will have an enduring impact on cardiological medicine.

See the text of the paper here:

https://www.ahajournals.org/doi/pdf/10.1161/CIRCULATIONAHA.118.035455

https://www.ahajournals.org/doi/suppl/10.1161/circulationaha.118.035455.

Similar stories

Emptage group successful with £1m MRC-AMED award

Congratulations to the group of Professor Nigel Emptage who have been awarded an MRC-AMED grant, worth £1m, in conjuction with the University of Tokyo and the RIKEN Center for Brain Science

Burton group wins image competition at Oxford BHF CRE Annual Symposium

This image of a blood clot composed of erythrocytes trapped by long fibrous chains of fibrin was judged the winner of the image competition at the BHF CRE 2022 Symposiium, held in December. In this image we can see false coloured erythrocytes (classic biconcave appearance around 5-10 µm in diameter) wrapped by fibrin network.

Understanding the brain at Didcot Girls School Science Club

A group of researchers and students led by Dr Tim Viney visited Didcot Girls School to run a ‘hands on’ event about the brain at the school’s Science Club.

Raised intracellular chloride levels underlie the effects of tiredness in cortex

The feeling of being tired is familiar to everyone. As we know from our own experience, an extended period of wakefulness results in a decline in our performance levels, and the desire to sleep becomes almost irresistible. When you then fall asleep, your sleep is deeper and more consolidated than usual. And yet after just one night of uninterrupted sleep, you can feel refreshed and “back to normal”!

Consequences of Tau pathology on hippocampal pyramidal neurons and network activity in ageing mice

Pathological hyperphosphorylated forms of the microtubule-associated binding protein Tau (pTau) are commonly found in people with neurodegenerative diseases, including Alzheimer’s disease, Corticobasal degeneration, and Progressive supranuclear palsy.